Current/ Expected Orderbook/ Pending Orders?

The LOIs (Letters of Intent) already commercialized amount to approximately Rs. 4,800 crores. Of this, Rs. 2,600 crores worth of LOIs were signed in FY'22, with annual revenue of around Rs. 450-500 crores. Current realized revenue from these is about Rs. 250 crores, expected to peak by FY'26-27. LOIs signed in FY'23 total about Rs. 1,000 crores, expected to contribute roughly Rs. 150 crores per year starting FY'26, ramping up in FY'27-FY'28. Additional LOIs and new molecules are in the process of commercialization, predicting growth in volumes and revenues from FY'26 onwards. Overall, the comp

Any current/future new fundraising through debt or equity?

No significant new external debt is planned to finance growth in the near term. Working capital absorption is expected to stabilize, with sufficient existing working capital to support growth. Rs.270 crores from preferential shares and warrants are expected in Q1 FY'26, which will be used to repay around Rs.200 crores of debt in H1 FY'26. Term debt repayment will largely be completed by mid-next year, with net cash position approaching zero net debt. CAPEX is mostly completed except for maintenance; no major incremental CAPEX requiring new funding is anticipated. The management plans to reduce

Any current/future capex/capital investment/strategic investment?

Completed CAPEX of Rs.610 crores as of September 30, 2024; remaining CAPEX to be completed over the next two quarters in FY'25. Large part of CAPEX related to capacity expansion and new facilities nearing completion, with trial runs underway. No significant CAPEX planned going forward except maintenance CAPEX. Backward integration includes strategic investment in Tanfac (24-25% stake) specializing in hydrogen fluoride (HF), with expanded plant capacity from 14,150 MT to 29,730 MT commissioned in October 2024. New 9.2 MW hybrid power project (solar and wind) commercialized in October 20

Future growth expectations in sales/revenue/volumes?

Anticipated growth in H2 FY'25 due to volume uptick, especially from pharma and polymer segments growing at 15%+ each. Agrochemical and international business expected to pick up in H2 FY'25, driving volume and revenue growth. New molecules launched last year are gaining momentum, contributing to incremental revenue. LOIs commercialized in FY'22 expected to ramp up revenue from Rs.250 crores towards a peak in FY'26-27. New LOIs signed in FY'23 (~Rs.1,000 crores) will start contributing from FY'26, with ramp-up over FY'27-28. FY'26 onwards visibility is positive with expected growth d

Future growth expectations in earnings/operating earnings/profits/EPS?

FY'25 revenue expected to be similar to FY'24, with a recovery starting from Q3 FY'25 due to increased polymer and pharma contributions and new contracts. FY'26 anticipated to mark a return to growth, driven by agrochemicals and ramp-up of pharma and polymer segments. EBITDA margins likely to remain in the 25%-28% range, with comfort around 25%-27% guidance currently. ROCE targeted to revert to high teens to 20s, aided by asset utilization improvements and normalization of working capital. New molecules (17 launched in FY'24 plus 3 in H1 FY'25) expected to contribute meaningfully, espe

Anupam Rasayan India LtdQ2 FY25Chemicals & Petrochemicals

Anupam Rasayan India Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,182P/E: 77.0Market Cap: ₹13.5K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Anticipated growth in H2 FY'25 due to volume uptick, especially from pharma and polymer segments growing at 15%+ each.
Agrochemical and international business expected to pick up in H2 FY'25, driving volume and revenue growth.
New molecules launched last year are gaining momentum, contributing to incremental revenue.
LOIs commercialized in FY'22 expected to ramp up revenue from Rs.250 crores towards a peak in FY'26-27.
New LOIs signed in FY'23 (~Rs.1,000 crores) will start contributing from FY'26, with ramp-up over FY'27-28.
FY'26 onwards visibility is positive with expected growth driven by increased volumes and stable prices.
Medium-term revenue target (3-4 years) standalone Rs.3,000 crore range, excluding Tanfac.
Confident of volume growth backed by strong order book and customer demand recovery post-soft H1 FY'25.

Margin guidance

Category 3

FY'25 revenue expected to be similar to FY'24, with a recovery starting from Q3 FY'25 due to increased polymer and pharma contributions and new contracts.
FY'26 anticipated to mark a return to growth, driven by agrochemicals and ramp-up of pharma and polymer segments.
EBITDA margins likely to remain in the 25%-28% range, with comfort around 25%-27% guidance currently.
ROCE targeted to revert to high teens to 20s, aided by asset utilization improvements and normalization of working capital.
New molecules (17 launched in FY'24 plus 3 in H1 FY'25) expected to contribute meaningfully, especially in pharma segment growing into 20s% medium term.
Debt reduction planned: significant repayment (~200+ crore) in H1 FY'26 expected from preferential shares and warrants inflow, aiming for three-digit debt by mid-next year.
Working capital expected to stabilize and eventually reduce, supporting free cash flow generation and debt lowering.

See what Anupam Rasayan India Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

No significant new external debt is planned to finance growth in the near term.
Working capital absorption is expected to stabilize, with sufficient existing working capital to support growth.
Rs.270 crores from preferential shares and warrants are expected in Q1 FY'26, which will be used to repay around Rs.200 crores of debt in H1 FY'26.
Term debt repayment will largely be completed by mid-next year, with net cash position approaching zero net debt.
CAPEX is mostly completed except for maintenance; no major incremental CAPEX requiring new funding is anticipated.
The management plans to reduce debt significantly from current levels (~Rs.1,200 crores) to three digits through free cash flow and preferential share infusion.

Order book

Yes

The LOIs (Letters of Intent) already commercialized amount to approximately Rs. 4,800 crores.
Of this, Rs. 2,600 crores worth of LOIs were signed in FY'22, with annual revenue of around Rs. 450-500 crores.
Current realized revenue from these is about Rs. 250 crores, expected to peak by FY'26-27.
LOIs signed in FY'23 total about Rs. 1,000 crores, expected to contribute roughly Rs. 150 crores per year starting FY'26, ramping up in FY'27-FY'28.
Additional LOIs and new molecules are in the process of commercialization, predicting growth in volumes and revenues from FY'26 onwards.
Overall, the company anticipates ramp-ups and monetization of these orders over FY'26 and FY'27, contributing significantly to future growth.

See what Anupam Rasayan India Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Completed CAPEX of Rs.610 crores as of September 30, 2024; remaining CAPEX to be completed over the next two quarters in FY'25.
Large part of CAPEX related to capacity expansion and new facilities nearing completion, with trial runs underway.
No significant CAPEX planned going forward except maintenance CAPEX.
Backward integration includes strategic investment in Tanfac (24-25% stake) specializing in hydrogen fluoride (HF), with expanded plant capacity from 14,150 MT to 29,730 MT commissioned in October 2024.
New 9.2 MW hybrid power project (solar and wind) commercialized in October 2024, expected to save ~Rs.15 crores annually; combined with earlier 17.9 MW investment expected to meet 65% of electricity needs via green energy.
Focus on operational efficiency, cost optimization, and funding growth without need for external debt in the near term.

Track Anupam Rasayan India Ltd — get its next earnings analysis in your feed

How does Anupam Rasayan India Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisAnupam Rasayan India Ltd

Rev 3Mar 3

See where Anupam Rasayan India Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Anupam Rasayan India Ltd rank in Chemicals & Petrochemicals?

Compare Anupam Rasayan India Ltd against every Chemicals & Petrochemicals company (Q2 FY25) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Anupam Rasayan India Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Alufluoride Ltd (Q1 FY27)
Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr
POCL Enterprises Ltd (Q1 FY27)
466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto
Deepak Nitrite Ltd (Q2 FY27)
Q2 FY27 total revenue: ₹3,091 crore, up 61% YoY (Page 1, 4, 5, 6, 10, 11) . Key investor presentation takeaways from Deepak Nitrite Ltd's Q2 FY27 investor prese
Privi Speciality Chemicals Ltd (Q2 FY27)
19,239.47 lakhs (approximately 33.9% growth). Key results statement takeaways from Privi Speciality Chemicals Ltd's Q2 FY27 results statement — and how it ranks

Compare:vs Solar Industries vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Anupam Rasayan India Ltd Q2 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Anupam Rasayan India Ltd rank in Chemicals & Petrochemicals?

Continue your research

What Anupam Rasayan India Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season